Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition

Part of paid clinical trials in San Francisco, California.

Sponsor
MedPacto, Inc.
Study ID
NCT04064190
Phase
PHASE2
Status
Withdrawn

Conditions

  • Advanced Urothelial Carcinoma
  • Urothelial Carcinoma Recurrent

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is Phase 2, open label, non randomized single arm study to determine whether the administration of vactosertib with durvalumab will provide meaningful increases in the Overall Response Rate (ORR) in patients with urothelial cancers that fail to achieve a response with anti-PD-1/PD-L1 based regimens

Key Dates

Start date
Dec 13, 2019
Status verified
Dec 2024
Primary completion
Dec 30, 2023
Completion
Dec 30, 2024

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Vactosertib+Durvalumab
    Vactosertib will be administered in combination with standard dose of durvalumab every four weeks.

Primary Outcome Measure

Overall Response Rate [ Time Frame: 12months ]

Locations (2)

FacilityCityStateZIPSite coordinators
University of California San FranciscoSan FranciscoCalifornia94158-
Roswell Park Comprehensive Cancer CenterBuffaloNew York14263-

Find similar trials in San Francisco, CA

By research site
University of California San Francisco· San Francisco, CARoswell Park Comprehensive Cancer Center· Buffalo, NY

Related Studies